{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T19:00:51Z","timestamp":1782932451346,"version":"3.54.5"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"1","funder":[{"DOI":"10.13039\/501100001826","name":"Netherlands Organisation for Health Research and Development (ZonMW)","doi-asserted-by":"crossref","award":["1520020301"],"award-info":[{"award-number":["1520020301"]}],"id":[{"id":"10.13039\/501100001826","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Orphanet J Rare Dis"],"published-print":{"date-parts":[[2017,12]]},"DOI":"10.1186\/s13023-017-0636-y","type":"journal-article","created":{"date-parts":[[2017,5,11]],"date-time":"2017-05-11T21:37:45Z","timestamp":1494538665000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Aggregated N-of-1 trials for unlicensed medicines for small populations: an assessment of a trial with ephedrine for myasthenia gravis"],"prefix":"10.1186","volume":"12","author":[{"given":"Stephanie S.","family":"Weinreich","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charlotte","family":"Vrinten","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marja R.","family":"Kuijpers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander F.","family":"Lipka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kirsten J. M.","family":"Schimmel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erik W.","family":"van Zwet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christine","family":"Gispen-de Wied","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yechiel A.","family":"Hekster","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan J. G. M.","family":"Verschuuren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martina C.","family":"Cornel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2017,5,12]]},"reference":[{"key":"636_CR1","unstructured":"Parliamentary documentation; Tweede Kamer der Staten Generaal. Visie op geneesmiddelen: Nieuwe geneesmiddelen snel bij de pati\u00ebnt tegen aanvaardbare kosten. Brief van de minister van Volksgezondheid, Welzijn en Sport. [View on medicines: new medicines quickly to patients at acceptable costs. Letter from the Minister of Health, Welfare and Sport]. No. 29477\u2013358. January 29 2016. 2016 [4\/30\/2016]. Available from: \nhttps:\/\/www.rijksoverheid.nl\/documenten\/kamerstukken\/2016\/01\/29\/kamerbrief-over-visie-op-geneesmiddelen\n\n. Accessed 25 Jan 2017."},{"key":"636_CR2","unstructured":"National Health Care Institute (Zorginstituut Nederland). Farmacotherapeutisch Kompas. Vergoeding niet-geregistreerde indicaties, niet-geregistreerde geneesmiddelen en apotheekbereidingen [Reimbursement of unlicensed indications, unlicensed medicines and compounded medicines] 2016. Available from: \nhttps:\/\/www.farmacotherapeutischkompas.nl\/algemeen\/niet-geregistreerde-indicaties\n\n. Accessed 26 Apr 2017."},{"key":"636_CR3","doi-asserted-by":"crossref","first-page":"c6456","DOI":"10.1136\/bmj.c6456","volume":"341","author":"RE Ferner","year":"2010","unstructured":"Ferner RE, Hughes DA. The problem of orphan drugs. BMJ. 2010;341:c6456.","journal-title":"BMJ"},{"key":"636_CR4","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1007\/s00228-011-1173-6","volume":"68","author":"R Lerose","year":"2012","unstructured":"Lerose R, Musto P, Aieta M, Papa C, Tartarone A. Off-label use of anti-cancer drugs between clinical practice and research: the Italian experience. Eur J Clin Pharmacol. 2012;68:505\u201312.","journal-title":"Eur J Clin Pharmacol"},{"key":"636_CR5","unstructured":"Parliamentary documentation; Tweede Kamer der Staten Generaal. Beoordeling zorg basispakket Zvw. Brief van de Minister van Volksgezonheid, Welzijn en Sport. [Assessing care for the basic health care package. Letter from the Minister of Health, Welfare and Sport.] no. 2015D38214. October 9 2015. 2015 [10\/05\/2016]. Available from: \nwww.rijksoverheid.nl\/documenten\/kamerstukken\/2015\/10\/09\/kamerbrief-over-beoordeling-zorg-basispakket-zvw\n\n. Accessed 25 Jan 2017."},{"key":"636_CR6","unstructured":"Regulation (EC) No 141\/2000 of the European Parliament and of the Council of 16 December 1999 on orphan medicinal products. 1999. [updated 12\/16\/1999141\/2000]. Available from: \nhttp:\/\/eur-lex.europa.eu\/LexUriServ\/LexUriServ.do?uri=OJ:L:2000:018:0001:0005:en:PDF\n\n. Accessed 25 Jan 2017."},{"key":"636_CR7","unstructured":"Medicines Evaluation Board. Strategic Business Plan 2014\u20132018. 2013. Available from: \nhttp:\/\/english.cbg-meb.nl\/documents\/publications\/2013\/06\/05\/sbp-2014-2018\n\n. Accessed 25 Jan 2017."},{"key":"636_CR8","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/jcpt.12006","volume":"38","author":"M Dooms","year":"2013","unstructured":"Dooms M, Pince H, Simoens S. Do we need authorized orphan drugs when compounded medications are available? J Clin Pharm Ther. 2013;38:1\u20132.","journal-title":"J Clin Pharm Ther"},{"key":"636_CR9","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1016\/j.jclinepi.2010.12.019","volume":"64","author":"S Gupta","year":"2011","unstructured":"Gupta S, Faughnan ME, Tomlinson GA, Bayoumi AM. A framework for applying unfamiliar trial designs in studies of rare diseases. J Clin Epidemiol. 2011;64:1085\u201394.","journal-title":"J Clin Epidemiol"},{"key":"636_CR10","doi-asserted-by":"crossref","first-page":"161","DOI":"10.2217\/pme.11.7","volume":"8","author":"EO Lillie","year":"2011","unstructured":"Lillie EO, Patay B, Diamant J, Issell B, Topol EJ, Schork NJ. The n-of-1 clinical trial: the ultimate strategy for individualizing medicine? Per Med. 2011;8:161\u201373.","journal-title":"Per Med"},{"key":"636_CR11","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1186\/1750-1172-8-48","volume":"8","author":"C Cornu","year":"2013","unstructured":"Cornu C, Kassai B, Fisch R, Chiron C, Alberti C, Guerrini R, et al. Experimental designs for small randomised clinical trials: an algorithm for choice. Orphanet J Rare Dis. 2013;8:48.","journal-title":"Orphanet J Rare Dis"},{"key":"636_CR12","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1017\/S0266462314000464","volume":"30","author":"K Facey","year":"2014","unstructured":"Facey K, Granados A, Guyatt G, Kent A, Shah N, van der Wilt GJ, et al. Generating health technology assessment evidence for rare diseases. Int J Technol Assess Health Care. 2014;30:416\u201322.","journal-title":"Int J Technol Assess Health Care"},{"key":"636_CR13","doi-asserted-by":"crossref","first-page":"g6802","DOI":"10.1136\/bmj.g6802","volume":"349","author":"JJ Gagne","year":"2014","unstructured":"Gagne JJ, Thompson L, O\u2019Keefe K, Kesselheim AS. Innovative research methods for studying treatments for rare diseases: methodological review. BMJ. 2014;349:g6802.","journal-title":"BMJ"},{"key":"636_CR14","unstructured":"European Medicines Agency. Guideline on clinical trials in small populations (CHMP\/EWP\/83561\/2005). 2006. [5\/3\/2016]. Available from: \nhttp:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/Scientific_guideline\/2009\/09\/WC500003615.pdf\n\n. Accessed 25 Jan 2017."},{"key":"636_CR15","series-title":"AHRQ Publication No. 13(14)-EHC122-EF","volume-title":"Design and Implementation of N-of-1 Trials: A User\u2019s Guide","author":"The DEcIDE Methods Center of N-of-1 Guidance Panel","year":"2014","unstructured":"The DEcIDE Methods Center of N-of-1 Guidance Panel. Design and Implementation of N-of-1 Trials: A User\u2019s Guide, AHRQ Publication No. 13(14)-EHC122-EF. Rockville: Report No.: 13(14)-EHC122-EF; 2014."},{"key":"636_CR16","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1016\/j.jclinepi.2010.05.009","volume":"64","author":"J Nikles","year":"2011","unstructured":"Nikles J, Mitchell GK, Schluter P, Good P, Hardy J, Rowett D, et al. Aggregating single patient (n-of-1) trials in populations where recruitment and retention was difficult: the case of palliative care. J Clin Epidemiol. 2011;64:471\u201380.","journal-title":"J Clin Epidemiol"},{"key":"636_CR17","doi-asserted-by":"crossref","first-page":"h1793","DOI":"10.1136\/bmj.h1793","volume":"350","author":"L Shamseer","year":"2015","unstructured":"Shamseer L, Sampson M, Bukutu C, Schmid CH, Nikles J, Tate R, et al. CONSORT extension for reporting N-of-1 trials (CENT) 2015: Explanation and elaboration. BMJ. 2015;350:h1793.","journal-title":"BMJ"},{"key":"636_CR18","unstructured":"OCEBM Levels of Evidence Working Group. The Oxford Levels of Evidence 2. 2011 [05\/10\/2016]. Available from: \nhttp:\/\/www.cebm.net\/index.aspx?o=5653\n\n. Accessed 25 Jan 2017."},{"key":"636_CR19","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1016\/j.jpainsymman.2015.03.009","volume":"50","author":"GK Mitchell","year":"2015","unstructured":"Mitchell GK, Hardy JR, Nikles CJ, Carmont SA, Senior HE, Schluter PJ, et al. The Effect of Methylphenidate on Fatigue in Advanced Cancer: An Aggregated N-of-1 Trial. J Pain Symptom Manage. 2015;50:289\u201396.","journal-title":"J Pain Symptom Manage"},{"key":"636_CR20","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1016\/S0895-4356(96)00429-5","volume":"50","author":"DR Zucker","year":"1997","unstructured":"Zucker DR, Schmid CH, McIntosh MW, D\u2019Agostino RB, Selker HP, Lau J. Combining single patient (N-of-1) trials to estimate population treatment effects and to evaluate individual patient responses to treatment. J Clin Epidemiol. 1997;50:401\u201310.","journal-title":"J Clin Epidemiol"},{"key":"636_CR21","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1071\/AH09654","volume":"34","author":"J Nikles","year":"2010","unstructured":"Nikles J, Mitchell GK, Clavarino A, Yelland MJ, Del Mar CB. Stakeholders\u2019 views on the routine use of n-of-1 trials to improve clinical care and to make resource allocation decisions for drug use. Aust Health Rev. 2010;34:131\u20136.","journal-title":"Aust Health Rev"},{"key":"636_CR22","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1097\/MLR.0b013e318215d90d","volume":"49","author":"NB Gabler","year":"2011","unstructured":"Gabler NB, Duan N, Vohra S, Kravitz RL. N-of-1 trials in the medical literature: a systematic review. Med Care. 2011;49:761\u20138.","journal-title":"Med Care"},{"key":"636_CR23","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1016\/S1474-4422(07)70329-0","volume":"7","author":"RA Hughes","year":"2008","unstructured":"Hughes RA, Donofrio P, Bril V, Dalakas MC, Deng C, Hanna K, et al. Intravenous immune globulin (10% caprylate-chromatography purified) for the treatment of chronic inflammatory demyelinating polyradiculoneuropathy (ICE study): a randomised placebo-controlled trial. Lancet Neurol. 2008;7:136\u201344.","journal-title":"Lancet Neurol"},{"key":"636_CR24","first-page":"A5479","volume":"157","author":"JM Heymans","year":"2013","unstructured":"Heymans JM, Kleijnen S, Verstijnen IM. \u2018Fitting\u2019 evidence preferable when evaluating effectiveness of interventions. Ned Tijdschr Geneeskd. 2013;157:A5479.","journal-title":"Ned Tijdschr Geneeskd"},{"key":"636_CR25","doi-asserted-by":"crossref","first-page":"e007863","DOI":"10.1136\/bmjopen-2015-007863","volume":"5","author":"C Vrinten","year":"2015","unstructured":"Vrinten C, Lipka AF, van Zwet EW, Schimmel KJ, Cornel MC, Kuijpers MR, et al. Ephedrine as add-on therapy for patients with myasthenia gravis: protocol for a series of randomised, placebo-controlled n-of-1 trials. BMJ Open. 2015;5:e007863.","journal-title":"BMJ Open"},{"key":"636_CR26","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1111\/j.1468-1331.2010.03019.x","volume":"17","author":"GO Skeie","year":"2010","unstructured":"Skeie GO, Apostolski S, Evoli A, Gilhus NE, Illa I, Harms L, et al. Guidelines for treatment of autoimmune neuromuscular transmission disorders. Eur J Neurol. 2010;17:893\u2013902.","journal-title":"Eur J Neurol"},{"key":"636_CR27","first-page":"CD010028","volume":"12","author":"C Vrinten","year":"2014","unstructured":"Vrinten C, van der Zwaag AM, Weinreich SS, Scholten RJ, Verschuuren JJ. Ephedrine for myasthenia gravis, neonatal myasthenia and the congenital myasthenic syndromes. Cochrane Database Syst Rev. 2014;12:CD010028.","journal-title":"Cochrane Database Syst Rev"},{"key":"636_CR28","unstructured":"European Medicines Agency. 2016 [updated 2016]. Available from: \nhttp:\/\/www.ema.europa.eu\/ema\/index.jsp\n\n. Accessed 25 Jan 2017."},{"key":"636_CR29","doi-asserted-by":"publisher","DOI":"10.1016\/j.nmd.2016.11.009","author":"AF Lipka","year":"2016","unstructured":"Lipka AF, Vrinten C, van Zwet EW, Schimmel KJ, Cornel MC, Kuijpers MR, et al. Ephedrine treatment for autoimmune myasthenia gravis. Neuromuscul Disord. 2016. doi:\n10.1016\/j.nmd.2016.11.009\n\n.","journal-title":"Neuromuscul Disord"},{"key":"636_CR30","unstructured":"Ephedrine as add-on therapy for patients with myasthenia gravis 2014. Available from: \nhttps:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2014-001355-23\/NL\n\n."},{"issue":"6","key":"636_CR31","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1093\/intqhc\/mzm042","volume":"19","author":"A Tong","year":"2007","unstructured":"Tong A, Sainsbury P, Craig J. Consolidated criteria for reporting qualitative research (COREQ): a 32-item checklist for interviews and focus groups. Int J Qual Health Care. 2007;19(6):349\u201357.","journal-title":"Int J Qual Health Care"},{"key":"636_CR32","first-page":"175","volume":"55","author":"CJ Nikles","year":"2005","unstructured":"Nikles CJ, Clavarino AM, Del Mar CB. Using n-of-1 trials as a clinical tool to improve prescribing. Br J Gen Pract. 2005;55:175\u201380.","journal-title":"Br J Gen Pract"},{"key":"636_CR33","unstructured":"National Health Care Institute (Zorginstiuut Nederland). Assessment of \u2018established medical science and medical practice\u2019 (update 2015). 2015. Available from: \nhttps:\/\/english.zorginstituutnederland.nl\/publications\/reports\/2015\/01\/19\/assessment-of-%E2%80%98established-medical-science-and-medical-practice\n\n. Accessed 25 Jan 2017."},{"key":"636_CR34","doi-asserted-by":"crossref","first-page":"966","DOI":"10.1002\/sim.6739","volume":"35","author":"S Senn","year":"2016","unstructured":"Senn S. Mastering variation: variance components and personalised medicine. Stat Med. 2016;35:966\u201377.","journal-title":"Stat Med"},{"key":"636_CR35","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1186\/s12883-015-0294-4","volume":"15","author":"BC Stunnenberg","year":"2015","unstructured":"Stunnenberg BC, Woertman W, Raaphorst J, Statland JM, Griggs RC, Timmermans J, et al. Combined N-of-1 trials to investigate mexiletine in non-dystrophic myotonia using a Bayesian approach; study rationale and protocol. BMC Neurol. 2015;15:43.","journal-title":"BMC Neurol"},{"key":"636_CR36","doi-asserted-by":"crossref","first-page":"2708","DOI":"10.1001\/jama.1993.03510220064035","volume":"270","author":"EB Larson","year":"1993","unstructured":"Larson EB, Ellsworth AJ, Oas J. Randomized clinical trials in single patients during a 2-year period. JAMA. 1993;270:2708\u201312.","journal-title":"JAMA"},{"key":"636_CR37","unstructured":"National Health Care Institute (Zorginstituut Nederland). Guideline for economic evaluations in healthcare. 2016. Available from: \nhttps:\/\/english.zorginstituutnederland.nl\/publications\/reports\/2016\/06\/16\/guideline-for-economic-evaluations-in-healthcare\n\n. Accessed 25 Jan 2017."},{"key":"636_CR38","first-page":"1125","volume":"34","author":"AM Huber","year":"2007","unstructured":"Huber AM, Tomlinson GA, Koren G, Feldman BM. Amitriptyline to relieve pain in juvenile idiopathic arthritis: a pilot study using Bayesian metaanalysis of multiple N-of-1 clinical trials. J Rheumatol. 2007;34:1125\u201332.","journal-title":"J Rheumatol"},{"key":"636_CR39","doi-asserted-by":"publisher","unstructured":"Araujo A, Julious S, Senn S. Understanding variation in sets of N-of-1 trials. PLoS One. 2016. doi:\n10.1371\/journal.pone.016716740\n\n.","DOI":"10.1371\/journal.pone.016716740"},{"key":"636_CR40","unstructured":"National Health Care Institute. Farmacotherapeutisch Kompas. Begrippenlijst: rationele farmacotherapie. 2016. Available from: \nhttps:\/\/www.farmacotherapeutischkompas.nl\/algemeen\/niet-geregistreerde-indicaties\n\n. Accessed 26 Apr 2017."}],"container-title":["Orphanet Journal of Rare Diseases"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-017-0636-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2017,5,11]],"date-time":"2017-05-11T21:38:09Z","timestamp":1494538689000},"score":1,"resource":{"primary":{"URL":"http:\/\/ojrd.biomedcentral.com\/articles\/10.1186\/s13023-017-0636-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,5,12]]},"references-count":40,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2017,12]]}},"alternative-id":["636"],"URL":"https:\/\/doi.org\/10.1186\/s13023-017-0636-y","relation":{},"ISSN":["1750-1172"],"issn-type":[{"value":"1750-1172","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,5,12]]},"article-number":"88"}}